Glucagon-like-peptide-1 Receptor Agonists in Patients Receiving Maintenance Dialysis

NCT07017270 · Not yet recruiting

Last updated 2026-05-28

This clinical trial is testing whether a type of diabetes medication called GLP-1 receptor agonists can be safely and effectively used by people with kidney failure who are on regular dialysis.

Status Not yet recruiting Approved but enrollment has not started.

Phase Phase 4 Monitors a drug already on the market.

Type Interventional (clinical trial)

Design Randomized, open-label (no blinding) treatment study

Participants 100 people Planned (estimated).

Who can join Ages 18+ · all sexes

Timeline Started 2025-07 · est. completion 2027-09

Where 1 site · Canada

What this study is testing ClinicalTrials.gov NCT07017270 ↗

Description as written by the study sponsor.

This study aims to determine if GLP1RA is safe and tolerable in maintenance dialysis population, adherence, and feasibility of a larger definitive cardiovascular outcome trial in this population. Participants will be randomized 1:1 to either weekly subcutaneous semaglutide versus usual care and followed for 26 weeks.

Treatments tested

Semaglutide Pen Drug

Individuals randomized to this arm will take semaglutide once weekly. For participants receiving in-centre hemodialysis, the intervention may be administered during the dialysis session by nursing personnel based on the patient's preference.

Main thing measured	Adherence of Study Intervention
Sponsor	Unity Health Toronto
Conditions studied	Kidney Disease, Chronic, Diabetes, Dialysis, End Stage Kidney Disease (ESRD)
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT07017270 ↗